NASDAQ:ACRS Aclaris Therapeutics Q1 2026 Earnings Results & Report $3.83 +0.04 (+1.06%) Closing price 04:00 PM EasternExtended Trading$3.86 +0.03 (+0.86%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aclaris Therapeutics beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.15 versus the -$0.16 consensus estimate, while revenue of $2.00 million topped the $1.32 million estimate by $0.67 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeBefore Market OpensConference Call7:00 AM ET Aclaris Therapeutics EPS ResultsActual EPS-$0.15Consensus EPS -$0.16Beat/MissBeat by +$0.01One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersAclaris Therapeutics Revenue ResultsActual Revenue$2.00 millionExpected Revenue$1.32 millionBeat/MissBeat by +$674.00 thousandYoY Revenue GrowthN/AUpcoming EarningsAclaris Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aclaris Therapeutics Q1 2026 Earnings FAQ Did Aclaris Therapeutics beat earnings estimates for Q1 2026? Aclaris Therapeutics (NASDAQ:ACRS) reported earnings of -$0.15 per share for Q1 2026, beating the consensus estimate of -$0.16. The report was announced on Thursday, May 7, 2026. What was Aclaris Therapeutics' revenue for Q1 2026? Aclaris Therapeutics reported revenue of $2.00 million for Q1 2026, against a consensus estimate of $1.32 million. When is Aclaris Therapeutics' next earnings date? Aclaris Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Aclaris Therapeutics on the company's earnings history page. Aclaris Therapeutics Earnings HeadlinesAnalysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)October 8 at 3:36 PM | theglobeandmail.comAclaris Therapeutics (NASDAQ:ACRS) Stock Falls 6.5% - What's Next?October 5, 2026 | americanbankingnews.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 9 at 1:00 AM | Investors Alley (Ad)Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by Wall Street ZenOctober 3, 2026 | americanbankingnews.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Consensus Target Price of $11.33September 30, 2026 | americanbankingnews.comCraig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)September 19, 2026 | theglobeandmail.comSee More Aclaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email. Email Address About Aclaris TherapeuticsAclaris Therapeutics (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company’s research programs have centered on small-molecule treatments designed to address inflammatory and autoimmune conditions, including dermatologic and rheumatologic diseases. Aclaris’ lead investigational program is zunsemetinib (ATI-450), an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being evaluated for potential use in inflammatory conditions such as rheumatoid arthritis and psoriasis. The company has also advanced other investigational immune-modulating programs, including therapies targeting Janus kinase (JAK) and related signaling pathways. Historically, Aclaris developed Klisyri (tirbanibulin) ointment for the topical treatment of actinic keratosis, a precancerous skin condition. The company has conducted clinical development and commercial activities primarily in the United States, while pursuing potential partnerships and licensing arrangements for selected programs. Aclaris is headquartered in Wayne, Pennsylvania.View Aclaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
